Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
Products :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and . . . These forward-looking statements include, without limitation, anticipated financial performance for 2026; anticipated timing and results from the clinical development of R289; Rigel's intention to fund existing and new clinical development programs while anticipating positive net income for 2026; and our general statements regarding anticipated
Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL) Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
Rigel Provides Business Update and 2026 Outlook Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements
Rigel Reports First Quarter 2025 Financial Results and Provides . . . The revenue ranges above exclude approximately $40 0 million in non-cash revenue that Rigel expects to recognize in the second quarter of 2025 related to the release of the remaining cost share liability from Rigel's collaboration with Lilly for the development and commercialization of ocadusertib
Rigel Announces Conference Call and Webcast to Report Fourth Quarter . . . Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p m Eastern Time (1:30 p m Pacific Time) to discuss the financial results and give an update on the business Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international)
Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and . . . Coupled with Rigel's commitment to financial discipline, for the first time we generated full-year net income of more than $17 million and increased our cash balances by more than $20 million," said Raul Rodriguez, Rigel's president and CEO
Rigel Reports Third Quarter 2025 Financial Results and Provides . . . Rigel does not undertake any obligation to update forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements